Abstract
Bacterial survival requires an intact peptidoglycan layer, a three-dimensional exoskeleton that encapsulates the cytoplasmic membrane. Historically, the final steps of peptidoglycan synthesis are known to be carried out by D,D-transpeptidases, enzymes that are inhibited by the β-lactams, which constitute >50% of all antibacterials in clinical use. Here, we show that the carbapenem subclass of β-lactams are distinctly effective not only because they inhibit D,D-transpeptidases and are poor substrates for β-lactamases, but primarily because they also inhibit non-classical transpeptidases, namely the L,D-transpeptidases, which generate the majority of linkages in the peptidoglycan of mycobacteria. We have characterized the molecular mechanisms responsible for inhibition of L,D-transpeptidases of Mycobacterium tuberculosis and a range of bacteria including ESKAPE pathogens, and used this information to design, synthesize and test simplified carbapenems with potent antibacterial activity.
Similar content being viewed by others
References
WHO. Global Tuberculosis Report (World Health Organization, 2015).
Walsh, C. Antibiotics: Actions, Origins, Resistance Ch. 3 (ASM Press, 2003).
Hugonnet, J.E., Tremblay, L.W., Boshoff, H.I., Barry, C.E. 3rd & Blanchard, J.S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215–1218 (2009).
Wivagg, C.N., Bhattacharyya, R.P. & Hung, D.T. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis. J. Antibiot. (Tokyo) 67, 645–654 (2014).
Cordillot, M. et al. In vitro cross-linking of peptidoglycan by Mycobacterium tuberculosis l,d-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob. Agents Chemother. 57, 5940–5945 (2013).
Dhar, N. et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob. Agents Chemother. 59, 1308–1319 (2015).
Kaushik, A. et al. Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob. Agents Chemother. 59, 6561–6567 (2015).
Rullas, J. et al. Combinations of β-lactam antibiotics currently in clinical trials are efficacious in a DHP-I deficient mice model of TB infection. Antimicrob. Agents Chemother. 59, 4997–4999 (2015).
Gupta, R. et al. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16, 466–469 (2010).
Erdemli, S.B. et al. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2. Structure 20, 2103–2115 (2012).
Lavollay, M. et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J. Bacteriol. 190, 4360–4366 (2008).
Kumar, P. et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86, 367–381 (2012).
Schoonmaker, M.K., Bishai, W.R. & Lamichhane, G. Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams. J. Bacteriol. 196, 1394–1402 (2014).
Kim, H.S. et al. Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains. Acta Crystallogr. D Biol. Crystallogr. 69, 420–431 (2013).
Ekins, S. et al. Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models. PLoS One 8, e63240 (2013).
Li, W.J. et al. Crystal structure of L,D-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis. Cell Res. 23, 728–731 (2013).
Correale, S., Ruggiero, A., Capparelli, R., Pedone, E. & Berisio, R. Structures of free and inhibited forms of the L,D-transpeptidase LdtMt1 from Mycobacterium tuberculosis. Acta Crystallogr. D Biol. Crystallogr. 69, 1697–1706 (2013).
Meroueh, S.O., Minasov, G., Lee, W., Shoichet, B.K. & Mobashery, S. Structural aspects for evolution of β-lactamases from penicillin-binding proteins. J. Am. Chem. Soc. 125, 9612–9618 (2003).
Mainardi, J.L. et al. A novel peptidoglycan cross-linking enzyme for a β-lactam-resistant transpeptidation pathway. J. Biol. Chem. 280, 38146–38152 (2005).
Hikida, M., Kawashima, K., Yoshida, M. & Mitsuhashi, S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother. 30, 129–134 (1992).
Chambers, H.F., Turner, J., Schecter, G.F., Kawamura, M. & Hopewell, P.C. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49, 2816–2821 (2005).
Veziris, N., Truffot, C., Mainardi, J.L. & Jarlier, V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob. Agents Chemother. 55, 2597–2600 (2011).
England, K. et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 56, 3384–3387 (2012).
Diacon, A.H. et al. β-Lactams against tuberculosis—new trick for an old dog? N. Engl. J. Med. 375, 393–394 (2016).
Charnas, R.L., Fisher, J. & Knowles, J.R. Chemical studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry 17, 2185–2189 (1978).
Drawz, S.M. et al. Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 49, 329–340 (2010).
Silva, J.R. et al. Targeting the cell wall of Mycobacterium tuberculosis: A molecular modelling investigation of the interaction of imipenem and meropenem with L,D-transpeptidase 2. J. Biomol. Struct. Dyn. 34, 304–317 (2016).
Fung-Tomc, J.C. et al. Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39, 394–399 (1995).
Natsugari, H., Matsushita, Y., Yoshioka, K. & Matsui, S. 5,6-cis-Carbapenem-3-carboxylic acid derivatives and process for their preparation. Japan patent WO1983000867 (1983).
Abe, T., Hayashi, K., Isoda, T. & Kumagai, T. 2-((Pyridyl-substituted)thio)-carbapenem derivative. Japan patent JPH0812676 (1996).
Seki, M., Kondo, K. & Iwasaki, T. Efficient synthesis of 1β-methylcarbapenems based on the counter-attack strategy. J. Chem. Soc. Perkin Trans. I 23, 2851–2856 (1996).
Palmero, D. et al. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina. Arch. Bronconeumol. 51, e49–e52 (2015).
Payen, M.C. et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 16, 558–560 (2012).
De Lorenzo, S. et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur. Respir. J. 41, 1386–1392 (2013).
Desmond, E. Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes (Approved Standard) 2nd edn. vol. 31, M24–A2 (Clinical Laboratory Standard Institute, 2011).
Brammer Basta, L.A. et al. Loss of a functionally and structurally distinct ld-transpeptidase, LdtMt5, compromises cell wall integrity in mycobacterium tuberculosis. J. Biol. Chem. 290, 25670–25685 (2015).
Triboulet, S. et al. Inactivation kinetics of a new target of β-lactam antibiotics. J. Biol. Chem. 286, 22777–22784 (2011).
Minor, W., Cymborowski, M., Otwinowski, Z. & Chruszcz, M. HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 62, 859–866 (2006).
McCoy, A.J. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D Biol. Crystallogr. 63, 32–41 (2007).
Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).
Zwart, P.H. et al. Automated structure solution with the PHENIX suite. Methods Mol. Biol. 426, 419–435 (2008).
Terwilliger, T.C. et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D Biol. Crystallogr. 64, 61–69 (2008).
Afonine, P.V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352–367 (2012).
Maddry, J.A. et al. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb.) 89, 354–363 (2009).
Reynolds, R.C. et al. High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb.) 92, 72–83 (2012).
Gavan, T.L. & Town, M.A. A microdilution method for antibiotic susceptibility testing: an evaluation. Am. J. Clin. Pathol. 53, 880–885 (1970).
Acknowledgements
Assistance of V. Chauhan for protein expression is appreciated. We thank L. Basta for critical discussions. P. aeruginosa PA14 was a kind gift from S. Lory, Harvard University. Discovery Studio was kindly provided to S.E. and J.S.F. by Biovia. This study was supported by NIH awards R21AI111739 and DP2OD008459 to G.L. Structural results shown in this report are derived in part from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by UChicago Argonne, LLC, for the US Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357.
Author information
Authors and Affiliations
Contributions
P.K., protein/ligand, crystallization and structure studies; A.K., antibacterial potency, animal studies; E.P.L., antibacterial synthesis and mass-spectrometry, mechanism; S.-G.L., antibacterial synthesis (contributed equally with E.P.L.); R.M., D.T.B., enzyme kinetics; T.A.Z. and A.L.P., structure data analysis; S.E., antibacterial cheminformatics; S.L.G., crystal data collection/analysis; C.A.T., antibacterial design/synthesis, mass-spectrometry, data analysis, mechanism; J.S.F., antibacterial design/synthesis and data analysis; G.L., overall study conception, cloning, animal studies, data analysis. P.K., N.C.A. and G.L. prepared the manuscript and all authors contributed to the final draft.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Tables 1–12 and Supplementary Figures 1–9. (PDF 2555 kb)
Supplementary Note
Synthetic procedures. (PDF 828 kb)
Rights and permissions
About this article
Cite this article
Kumar, P., Kaushik, A., Lloyd, E. et al. Non-classical transpeptidases yield insight into new antibacterials. Nat Chem Biol 13, 54–61 (2017). https://doi.org/10.1038/nchembio.2237
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2237
- Springer Nature America, Inc.
This article is cited by
-
Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC–MS
Scientific Reports (2022)
-
Development of a penem antibiotic against Mycobacteroides abscessus
Communications Biology (2020)
-
Combination of Repurposed Drug Diosmin with Amoxicillin-Clavulanic acid Causes Synergistic Inhibition of Mycobacterial Growth
Scientific Reports (2019)
-
Structural insight into YcbB-mediated beta-lactam resistance in Escherichia coli
Nature Communications (2019)
-
Genome-scale fitness profile of Caulobacter crescentus grown in natural freshwater
The ISME Journal (2019)